Results 141 to 150 of about 19,791 (259)

Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE‐O Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims In the AMPLITUDE O trial, efpeglenatide reduced major cardiovascular events by 27% in 4076 individuals with Type 2 diabetes and established cardiovascular or kidney disease compared to placebo during a median follow‐up of 1.81 years. This exploratory mediation analysis evaluates the degree to which changes in measured clinical variables ...
Daniel Raaschou‐Oddershede, Christine R. Schwarz, Tanya Kovalova, Kelley R. Branch, Stefano Del Prato, Carolyn S. P. Lam, Renato D. Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar, Hertzel C. Gerstein   +10 more
wiley   +1 more source

Comment on "Sitagliptin, a DPP-4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial". [PDF]

J Diabetes
Ayesha S, Parveen U, Irshad NUN.
europepmc   +1 more source

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19. [PDF]

Diabetes Metab J, 2021
Rhee SY, Lee J, Nam H, Kyoung DS, Shin DW, Kim DJ.   +5 more
europepmc   +1 more source

Durability and Safety of Imeglimin as an Add‐On to DPP‐4 Inhibitors in Japanese Type 2 Diabetes: The 104‐Week FAMILIAR Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of imeglimin added to dipeptidyl peptidase‐4 (DPP‐4) inhibitors in Japanese patients with type 2 diabetes, focusing on glycemic durability and safety in elderly patients over 104 weeks. Materials and Methods This multicenter, randomized, placebo‐controlled trial comprised a 24‐week double ...
Masashi Shimoda, Takeshi Osonoi, Masahiro Iwamoto, Hideaki Kaneto, Kohei Kaku   +4 more
wiley   +1 more source

Clinical Outcomes with the Use of Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Among Patients with Diabetes Mellitus and COVID-19: A Systematic Review of Observational Studies. [PDF]

J Clin Med
Alkhalifah SA, Alshahrani WA, Alshehri AM, Al Yami MS.   +3 more
europepmc   +1 more source

Association Between Time in Range and Advanced Cardiovascular‐Kidney‐Metabolic Syndrome in Older Adults With Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Cardiovascular, kidney and metabolic diseases are pathophysiologically interrelated and are conceptualised within the cardiovascular‐kidney‐metabolic (CKM) syndrome framework. However, evidence linking continuous glucose monitoring (CGM) to CKM syndrome remains limited.
Hang Su, Jiaying Ni, Jinghao Cai, Wei Zhu, Yufei Wang, Jian Zhou, Jingyi Lu, Xiaojing Ma   +7 more
wiley   +1 more source

Sitagliptin, a DPP-4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial. [PDF]

J Diabetes
Gao W, Chen D, He H, Jiang N, Chen L, Ran X.   +5 more
europepmc   +1 more source

Dipeptidyl Peptidase (DPP)-4 Inhibitor Impairs the Outcomes of Patients with Type 2 Diabetes Mellitus After Curative Resection for Colorectal Cancer. [PDF]

Cancer Res Commun, 2021
Saito A, Kitayama J, Horie H, Koinuma K, Kawashima R, Ohzawa H, Yamaguchi H, Kawahira H, Mimura T, Lefor AK, Sata N.   +10 more
europepmc   +1 more source

The sorting nexin Snx21 promotes flotillin‐mediated endocytosis

The FEBS Journal, EarlyView.
In this study, we describe a novel function of the previously uncharacterized Snx21 protein as a specific positive regulator of flotillin‐mediated endocytic trafficking. Snx21 is recruited to endosomal membranes via binding to PI(3)P, and it colocalizes with flotillins on the surface of late endosomes.
Tamás Maruzs, Enikő Lakatos, Dalma Feil‐Börcsök, Gábor Juhász, Regina Mező, Asha Kiran Maddali, András Blastyák, Aladár Pettkó‐Szandtner, Hajnalka Laczkó‐Dobos, Gábor Juhász   +9 more
wiley   +1 more source

DPP-4 inhibitor linagliptin modulates myocardial metabolism in a model of coronary artery disease. [PDF]

JTCVS Open
Muir KC, Harris DD, Stone C, Kanuparthy M, Hamze J, Sellke FW.   +5 more
europepmc   +1 more source